Table 1.
Baseline characteristics.
| ALS mutation carriers (n = 60) |
Non-carriers (n = 73) |
p-value (carrier vs. non-carrier) | |||||
|---|---|---|---|---|---|---|---|
| Total | Male | Female | Total | Male | Female | ||
| Age (years) | 48.7 ± 14.9 | 53.1 ± 23.3 | 45.8 ± 21.2 | 47.2 ± 12.9 | 47.1 ± 38.2 | 47.7 ± 29.7 | 0.72 |
| Sex | 24 (40%) | 36 (60%) | 34 (46.6%) | 39 (53.4%) | 0.49 | ||
| NfL blood levels (pg/ml) | 14 (10–19) | 15 (10–31) | 13 (10–18) | 15 (10–21) | 15 (11–21) | 15 (10–21) | 0.60 |
| Mutations | |||||||
| C9orf72 | 28 | 7 | 21 | ||||
| SOD1 | 22 | 13 | 9 | ||||
| FUS | 4 | 1 | 3 | ||||
| KIF5A | 3 | 1 | 2 | ||||
| SETX | 1 | 1 | 0 | ||||
| TBK1 | 1 | 1 | 0 | ||||
| TDP43 | 1 | 0 | 1 | ||||
| Expected time to onset (years) | 4.0 (−6.0 to 14.0) | −3.0 (−13.5 to 13.5) | 7.0 (−3.0 to 17.0) | ||||
| Disease onset (paresis within observation period) | 12 (20%) | 9 (37.5%) | 3 (8.3%) | ||||
| Deceased (within observation period) | 4 (7%) | 3 (12.5%) | 1 (2.7%) | ||||
Data are n (%), mean ± SD, or median (IQR).
NfL: Neurofilament light chain.